Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Tarhini, Ahmad A ^a,b   Zahoor, Haris ^b   Yearley, Jennifer H ^c   Gibson, Christopher ^c   Rahman, Zahra ^b   Dubner, Rachel ^b   Rao, Uma N M ^a,b   Sander, Cindy ^a   Kirkwood, John M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Melanoma; PD 1; PD L1; Sentinel lymph node

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR; PROTEIN PD L1; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ARTICLE; BRESLOW THICKNESS; CANCER LOCALIZATION; CANCER SIZE; CLINICAL ARTICLE; CUTANEOUS MELANOMA; CUTANEOUS PARAMETERS; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTATIC MELANOMA; MICROMETASTASIS; MICROSCOPY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SENTINEL LYMPH NODE METASTASIS; SKIN ULCER; TUMOR CELL; ADJUVANT CHEMOTHERAPY; ADOLESCENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNE SYSTEM; LYMPHATIC METASTASIS; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD274; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM MICROMETASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84942578466     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0678-7     Document Type: Article

References (45)

1. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-34.
2. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99(19):12293-7. doi: 10.1073/pnas.192461099.
3. Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol. 2009;182(5):2816-26. doi: 10.4049/jimmunol.0803648.
4. Talay O, Shen CH, Chen L, Chen J. B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation. Proc Natl Acad Sci USA. 2009;106(8):2741-6. doi: 10.1073/pnas.0813367106.
5. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+regulatory T cells. Proc Natl Acad Sci USA. 2008;105(27):9331-6. doi: 10.1073/pnas.0710441105.
6. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clinl Oncol Off J Am Soc Clin Oncol. 2015;. doi: 10.1200/JCO.2014.59.4358.
7. Merelli B, Massi D, Cattaneo L, Mandala M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol/Hematol. 2014;89(1):140-65. doi: 10.1016/j.critrevonc.2013.08.002.
8. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004;101(49):17174-9. doi: 10.1073/pnas.0406351101.
9. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360-5. doi: 10.1073/pnas.0611533104.
10. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499-505. doi: 10.1002/cncr.22588.
11. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother CII. 2007;56(8):1173-82. doi: 10.1007/s00262-006-0266-z.
12. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(7):2151-7. doi: 10.1158/1078-0432.CCR-06-2746.
13. Zhao JM, Wu CP, Wang RC, Xu J, Zhu J, Wei J, et al. Expression and clinical significance of costimulatory molecule B7-H3 mRNA and B7-H3 protein in gastric carcinoma. Zhonghua wei chang wai ke za zhi=Chin J Gastrointest Surg. 2007;10(5):458-62.
14. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170(3):1257-66.
15. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. doi: 10.1038/nm730.
16. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(15):5094-100. doi: 10.1158/1078-0432.CCR-04-0428.
17. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005;104(10):2084-91. doi: 10.1002/cncr.21470.
18. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381-5. doi: 10.1158/0008-5472.can-05-4303.
19. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089-96 (65/3/1089 [pii]).
20. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008;111(7):3635-43. doi: 10.1182/blood-2007-11-123141.
21. Ramsay AJ, Dong Y, Hunt ML, Linn M, Samaratunga H, Clements JA, et al. Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J Biol Chem. 2008;283(18):12293-304. doi: 10.1074/jbc.M709493200.
22. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-48. doi: 10.1146/annurev.immunol.23.021704.115611.
23. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006;27(4):195-201. doi: 10.1016/j.it.2006.02.001.
24. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (Baltim Md 1950). 2009;182(9):5240-9. doi: 10.4049/jimmunol.0803245.
25. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63(19):6501-5.
26. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116(7):1757-66. doi: 10.1002/cncr.24899.
27. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2.
28. Ribas A, Hodi FS, Kefford R, editors. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). In: 50th annual meeting of the American society of clinical oncology; 2014.
29. Kefford R, Ribas A, Hamid O, editors. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. In: 50th annual meeting of the American society of clinical oncology, Chicago; 2014.
30. Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, et al. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther. 1997;281(1):420-7.
31. Weber JS MD, D'Angelo SP, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. In: Program and abstracts from the 39th European society for medical oncology congress, Madrid; 2014. (Abstract LBA3_PR).
32. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-30. doi: 10.1056/NEJMoa1412082.
33. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71. doi: 10.1038/nature13954.
34. Kefford RRA, Hamid O, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients with melanoma treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475). In: The 2014 ASCO annual meeting; 2014.
35. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-48.
36. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg. 1981;193(3):377-88.
37. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(16):3622-34.
38. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(36):6199-206. doi: 10.1200/JCO.2009.23.4799.
39. Tarhini AA, Thalanayar PM. Melanoma adjuvant therapy. Hematol Oncol Clin N Am. 2014;28(3):471-89. doi: 10.1016/j.hoc.2014.02.004.
40. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. doi: 10.1056/NEJMoa1200690.
41. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802.
42. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28. doi: 10.1056/NEJMoa1501824.
43. Hodi FSSM, Kluger HM, et al. Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial. In: The 2014 ASCO annual meeting; 2014.
44. Gettinger SSF, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status. In: The 2014 ASCO annual meeting; 2014.
45. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE 3rd. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 2006;66(1):517-26. doi: 10.1158/0008-5472.CAN-05-2429.